Despite the renewed surge, the disease burden has diminished significantly since the pandemic began. As of early August 2026, fewer than 6,000 U.S. deaths were associated with COVID-19, a drop of more than 60% compared to the same period last year and roughly ten times fewer than the death count in April 2020. This reduction is attributed to widespread population immunity from prior infection and vaccination, alongside the introduction of effective antiviral therapies. However, the virus remains a serious threat for older adults and those with compromised immune systems, including patients on immunosuppressant drugs for cancer treatment.
Older adults continue to bear the highest mortality risk. CDC data indicates that people aged 65 and older, who constitute 16% of the U.S. population, have accounted for 75% to 80% of pandemic deaths. A CDC analysis comparing data from October 2022 and September 2024 found that while infections and hospitalizations dropped, annual deaths remained stable at approximately 101,000. This persistence suggests that some deaths may have been preventable through better utilization of existing tools. Notably, a CDC report found that from June 2023 to September 2025, fewer than 40% of adults over 60 who visited outpatient clinics for COVID-19 received an antiviral prescription, despite guidelines recommending immediate treatment for high-risk patients.
Clinical guidelines and new regulatory approvals aim to close these treatment gaps. The Infectious Diseases Society of America (IDSA) 2025 guidelines recommend nirmatrelvir (Paxlovid) or remdesivir for high-risk patients with mild to moderate disease, while biologics are used for severe cases to mitigate extreme immune reactions. In June, the FDA approved ensitrelvir, marketed as Xocova, as the first antiviral authorized for post-exposure prophylaxis. A U.S. clinical trial showed that a five-day course of the drug reduced the risk of developing COVID-19 by 67% in exposed households, provided it is started within 72 hours of exposure. The drug is not recommended for pregnant individuals and does not replace vaccination.
Public health experts emphasize that while the overall risk has decreased, vulnerable groups require continued vigilance. Dr. John Brooks, a former CDC chief medical officer, noted that the current situation is a testament to global scientific progress but stressed that the virus remains dangerous for immunocompromised patients. With an estimated 18 million U.S. residents living with long COVID, reinfection can worsen debilitating symptoms. Health officials are encouraging clinicians to engage in conversations about vaccination with hesitant adults over 50, nearly half of whom have not been vaccinated in over a year. The next critical step involves ensuring the widespread distribution and uptake of the newly approved vaccines in early September.
One Comment